European oncologists add hypothermia to chemotherapy for soft tissue sarcoma
This article was originally published in Clinica
The European Society for Medical Oncology (ESMO) has issued guidance recommending that regional hyperthermia be combined with chemotherapy as the standard treatment for soft tissue sarcoma. The policy was debated at the ESMO congress in Stockholm, Sweden, last week. Evidence supporting the technique includes a study, headed by Dr Rolf Issels, of the Univeristy Hospital Medical Centre Grosshadern and Helmholtz Zentrum Munchen, which involved the BSD-2000 system by hyperthermia delivery specialist BSD Medical. The use of regional hyperthermia in combination with chemotherapy in high-grade soft tissue sarcomas almost doubled disease-free survival, compared with patients who received chemotherapy, radiotherapy or surgery alone, said the Salt Lake City, Utah firm.